Tissue Repair Ltd · ASX:TRP
Tissue Repair — Shareholder Meeting (October 2024)
11 slides from Tissue Repair's shareholder meeting presentation, Oct 25, 2024
Slide 1: AGM Progress Update
For personal use only Tissue Repair Limited AGM Progress Update Tony Charara Co-founder and CEO
Slide 2: Two separate workstreams in progress: chronic wounds and acute wounds
Two separate workstreams in progress – chronic wounds (venous leg ulcers) and acute wounds (aftercare of medical and aesthetic procedures) Glucoprime® For personal use only Chronic wounds (venous leg ulcers) Acute wounds (medical and aesthetic) Preclinical and safety Preclinical and safety Phase 1 C
Slide 3: Phase 3 screening has commenced, 7 sites online by end of October 2024
Phase 3 screening has commenced - 7 sites online by the end of October 2024 (target 30 sites by Q1 2025) for both trials Current key site status Metrics Summary For personal use only • BG002 has 17 sites selected in the US. Sites Pending Selection (Sanchez, Garret). Monthly Randomization estimates:
Slide 4: Phase 2 refresher: meta-analysis for chronic wounds
Phase 3 refresher - Meta analysis on two Phase 2 trials for chronic wounds . . . this signal is what we are powering Analysis included 147 patients from two Phase 2 trials which confirmed a strong signal of efficacy and demonstrated a 60% reduction in wound size vs placebo control (p=0.03). For pers
Slide 5: Need for affordable, effective new technologies to promote wound healing
We need affordable, effective new technologies to promote wound healing, TR987 has the potential to be a global scale front line therapy for chronic wounds > ease of use (topical), with excellent health economics having regard to efficacy For personal use only ● Huge numbers ○ Around 300,000 Austral
Slide 6: TR Pro+ is growing with a strong signal of market acceptance
TR Pro+ is growing and has demonstrated a strong signal of market acceptance. Around 35k per month in sales with consistent growth. For personal use only Orders are split 50:50 for new vs repeat More than 250 clinics have purchased TR Pro+ Laser resurfacing, skin needling and scar management With mi
Slide 7: Expanding indications to increase distribution while still selling as cosmetic
Expanding indications to increase distribution while still selling as cosmetic. TGA labelling not yet commenced. • Medical • Biopsy For personal use only • Hard-to-heal wounds • Skin cancer removal • Scar management • Dermatitis Day 1 Day 5 • Post solar keratosis treatment • Aesthetic • Skin needlin
Slide 8: New data on MOA
New data on MOA Refresher - Macrophages co-ordinate the healing process For personal use only M1 M2 • Activation of macrophages by Glucoprime® draws neutrophils and other macrophages to the wound site during the inflammatory phase. • M1 macrophages control the inflammatory phase (remove pathogens, p
Slide 9: Further clarity on the novel mode of action
Further clarity on the novel mode of action • The beta glucan in TR987®/TR Pro+® is purified from the cell wall of bakers’ yeast. • Beta glucans are complex polysaccharides composed of glucose monomers. • TR987®/TR Pro+® is a hydrogel with purified beta glucan (Glucoprime®) as the For personal use o
Slide 10: Confirmation of M2 macrophage stimulation
Confirmation of M2 macrophage stimulation A 12 month project with the University of South Australia (Prof. Allison Cowin) investigated the mode of action and found that Glucoprime®: • Accelerated healing in wounded mice as evidenced macroscopically and microscopically For personal use only • Elicite
Slide 11: In summary: significant opportunity ahead with a track record of achieving goals
In summary Tissue Repair has a significant opportunity ahead with a track record of achieving goals and navigating challenges Generated revenue now with strong growth TR Pro+TM Australian TAM +AUD100M TGA approved with marketing commencing Q1 2025 Founder strategy has Exploring approvals in China, U